Mini-Oral
Dato-DXd
ASCO Genitourinary Cancers Symposium | February 13-15, 2025
Tumor-agnostic
Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPION PanTumor01 study
Funda Meric-Bernstam